Skip to navigation Skip to content

Neuromyelitis optica spectrum disorder (NMOSD) in Pharmaceutical Benefits Scheme (PBS) 012-25030536

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised ravulizumab for patients with neuromyelitis optica spectrum disorder (NMOSD).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Neuromyelitis optica spectrum disorder (NMOSD) quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB382 form

Written

Electronic

S100:

ravulizumab

No

OPA

Must be treated by a:

  • neurologist
  • medical practitioner in consultation with a neurologist

Yes - delayed assessment due to DPMQ (cost) and free text field

Grandfather

PB383 form

Written

Electronic

S100:

ravulizumab

No

OPA

Must be treated by a:

  • neurologist
  • medical practitioner in consultation with a neurologist

Yes - delayed assessment due to DPMQ (cost) and free text field

Continuing

Telephone

Electronic

S100:

ravulizumab

No

OPA

Must be treated by a:

  • neurologist
  • medical practitioner in consultation with a neurologist

Yes